A Study of Nula-cel in People With Severe Sickle Cell Disease

Full Title

RESTORE: A Phase 1/2 Study of nula-cel in Autologous CD34+ Hematopoietic Stem Cells to Convert HbS to HbA for Treating Severe Sickle Cell Disease

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description

Contact

For more information or to see if you can join this study, please call Dr. Jaap Jans Boelens’ office at 212-639-3643.

Protocol
26-179
Phase
Phase I/II (phases 1 and 2 combined)
Investigator
Jaap-Jan Boelens
Co-Investigators
Maria Cancio
Moneeza Walji
Diseases
Pediatric Blood Disorders
Locations
Memorial Sloan Kettering Cancer Center
ClinicalTrials.gov ID
NCT04819841
ClinicalTrials.gov
Visit ClinicalTrials.gov for full clinical trial description